Fig. 5

MLN4924 enhances the antileukemia effect of Len. A–D K562 (A, B) and NB4 (C, D) cells with stable KDM5C knockdown were treated with lenalidomide (10 µM) for 4 (A and C) or 5 (B and D) days, and the cell proliferation was examined by CCK-8. shNC was used as a negative control. The data are shown as the means ± SEMs (n = 4), and Student’s t test was used to calculate the P values. *P < 0.05; ns: not significant. E–H K562, THP-1, KG-1, and primary AML cells were treated with MLN4924 (40 nM) for 18 h, and then treated with lenalidomide (10 µM) for 4 days. Cell viability was measured by a CCK-8 assay. The data are shown as the means ± SEMs (n = 4); **P < 0.01;***P < 0.001;****P < 0.0001; ns: not significant. I Proposed model for the regulation of KDM5C on the antileukemia effect of IMiDs